Understanding Psychedelic-Assisted Therapy: What Psychiatric Nurse Practitioners Need to Know
Psychedelic-assisted therapy (PAT)[1] is an emerging treatment modality that integrates the use of psychedelic substances, such as psilocybin, MDMA, or ketamine, with psychotherapy to treat a variety of mental health disorders. This innovative approach holds significant promise, particularly in cases where traditional therapies have failed. For Psychiatric Nurse Practitioners (PNPs), understanding the complexities of psychedelic-assisted therapy—its potential benefits, risks, and ethical considerations—is crucial to safely incorporating it into practice.
This article explores what Psychiatric Nurse Practitioners need to know about psychedelic-assisted therapy, highlighting the science behind it and illustrating its application with case studies to help PNPs gain a deeper understanding of this novel treatment approach.
The Science of Psychedelic-Assisted Therapy
Psychedelic substances[2] have been used for centuries in various cultural and spiritual contexts. In the modern era, they are being studied for their therapeutic potential. Research shows that psychedelics can temporarily alter the brain’s default mode network (DMN)[3], which is responsible for a person’s sense of self. These substances may promote neuroplasticity, facilitating new connections in the brain that enable individuals to confront deeply held emotional or psychological issues in a way that traditional therapy cannot.
Recent clinical trials have shown that psychedelic-assisted therapy can be effective for conditions like depression, post-traumatic stress disorder (PTSD)[4], anxiety, and substance use disorders. However, because these therapies are still in the experimental phase, they require careful management and a controlled setting, making the role of Psychiatric Nurse Practitioners[5] in these treatments pivotal.
Case Study 1: Psilocybin for Treatment-Resistant Depression
Patient Profile:
Laura, a 38-year-old woman, has struggled with severe, treatment-resistant depression for over a decade. Despite trying various medications and therapies, she continues to experience overwhelming feelings of hopelessness, low energy, and suicidal ideation.
Approach:
After a thorough psychiatric evaluation and the failure of traditional treatments, Laura is considered a candidate for psychedelic-assisted therapy with psilocybin, a naturally occurring psychedelic compound found in certain mushrooms. Psilocybin therapy is often used in conjunction with psychotherapy to help patients process trauma, emotional pain, and unaddressed psychological issues.
Initial Assessment and Screening: As with all psychedelic-assisted therapy, the first step involves careful screening. The Psychiatric Nurse Practitioner (PNP) ensures Laura is a good candidate for this therapy by ruling out contraindications (e.g., personal or family history of psychosis) and discussing her medical and psychiatric history. They also assess her mental readiness for the therapy, as the experience can be intense and emotionally challenging.
Therapeutic Setting and Administration: Under the supervision of a trained therapist and medical staff, Laura receives a controlled dose of psilocybin in a comfortable, supportive environment. The PNP plays a critical role in ensuring Laura’s physical and psychological safety during the session, monitoring her vitals, and providing emotional support.
Integration Therapy: After the psilocybin session, Laura participates in integration therapy. The PNP works closely with the therapist to help Laura process the insights gained during the psychedelic experience, which may involve confronting deep-seated emotions or past trauma. The goal is to use the experience as a catalyst for long-term change.
Follow-up and Monitoring: The PNP monitors Laura’s progress in subsequent sessions, assessing her mental health and adjusting the treatment plan as necessary. After several sessions, Laura reports a significant reduction in depressive symptoms and a renewed sense of hope.
Case Study 2: MDMA-Assisted Therapy for PTSD
Patient Profile:
Tom, a 42-year-old military veteran, has been diagnosed with severe PTSD following multiple combat tours. His symptoms include hypervigilance, flashbacks, emotional numbing, and insomnia. Tom has not found relief from traditional therapies or medications.
Approach:
MDMA (3,4-methylenedioxymethamphetamine)[6] is a synthetic substance known for its empathogenic effects, which facilitate deep emotional processing and connection. It has shown promise in treating PTSD when combined with psychotherapy. The use of MDMA in therapy aims to allow patients to confront traumatic memories without becoming overwhelmed by the emotions associated with them.
Screening and Consent: The PNP conducts a thorough screening to ensure Tom is a suitable candidate for MDMA-assisted therapy. Given the intensity of the MDMA experience, Tom is briefed on the potential effects, including heightened emotional sensitivity, and gives informed consent to proceed.
MDMA-Assisted Therapy Sessions: Tom participates in a series of therapy sessions in which MDMA is administered in a safe, clinical environment. The PNP is responsible for ensuring Tom’s physical safety, monitoring his vital signs, and ensuring the therapy team is ready to intervene if necessary. Throughout the session, Tom is encouraged to explore and process traumatic memories, facilitated by the emotional openness induced by MDMA.
Post-Therapy Integration: After each MDMA session, Tom engages in integration therapy, where he processes the emotions and insights from the session. The PNP plays an active role in ensuring Tom’s emotional well-being, providing support, and assisting in implementing coping strategies.
Ongoing Care: Following MDMA-assisted therapy, Tom reports a significant reduction in PTSD symptoms, including a decrease in flashbacks and nightmares. He continues with traditional therapy and support from his PNP, ensuring sustained recovery.
Case Study 3: Ketamine-Assisted Therapy for Severe Anxiety
Patient Profile:
James, a 28-year-old man, has struggled with severe anxiety for most of his adult life. His anxiety is characterized by constant worry, physical tension, and difficulty managing day-to-day tasks. Despite medication and therapy, his symptoms have not improved significantly.
Approach:
Ketamine, originally developed as an anesthetic, has gained recognition as a treatment for severe anxiety and depression.[7] When used in a therapeutic context, ketamine can rapidly reduce symptoms of anxiety, potentially offering a breakthrough for patients who have not responded to conventional treatments.
Evaluation and Preparation: The PNP assesses James for suitability, taking into account his medical and psychiatric history. The PNP also educates James on the possible effects of ketamine, which may include dissociation and vivid sensory experiences. Informed consent is obtained before the therapy begins.
Ketamine Administration: James receives a low-dose intravenous infusion of ketamine in a controlled, comfortable setting. The PNP closely monitors his vital signs and emotional state throughout the session. The aim is to provide a safe, supportive environment where James can confront and process his anxiety without being overwhelmed.
Post-Treatment Support: After the infusion, James engages in psychotherapy to help him integrate the insights gained from the session. The PNP plays a critical role in ensuring James feels supported and safe during this phase, offering emotional guidance as needed.
Long-Term Management: Over the course of several ketamine sessions, James reports significant improvement in his anxiety levels, including decreased physical tension and improved mood regulation. The PNP monitors his progress and continues to provide support as he works through underlying issues contributing to his anxiety.
Conclusion
Psychedelic-assisted therapy[8] is a promising and innovative treatment modality for individuals with treatment-resistant mental health conditions. Psychiatric Nurse Practitioners play a pivotal role in ensuring the safety, effectiveness, and ethical administration of these therapies. Through careful screening, administration, and post-therapy integration, PNPs can help patients process deep psychological issues and achieve profound healing.
As the field of psychedelic-assisted therapy continues to grow, Psychiatric Nurse Practitioners are well-positioned to be at the forefront, providing compassionate, evidence-based care to those in need. By incorporating psychedelic therapies into their practice, PNPs can offer hope to patients who have struggled with mental health conditions for years, helping them access new pathways to healing and transformation.
Would you like to be part of a growing community of exceptional psychiatric nurse practitioners on LinkedIn? If so, click here to join our SWEET Psych NP LinkedIn page.
References
[1] Reiff, Collin M., et al. "Psychedelics and psychedelic-assisted psychotherapy." American Journal of Psychiatry 177.5 (2020): 391-410.
[2] Schenberg, Eduardo Ekman. "Psychedelic-assisted psychotherapy: A paradigm shift in psychiatric research and development." Frontiers in pharmacology 9 (2018): 733.
[3] Ruban, Anastasia, and Aleksandra A. Kołodziej. "Changes in default-mode network activity and functional connectivity as an indicator of psychedelic-assisted psychotherapy effectiveness." Neuropsychiatria i Neuropsychologia/Neuropsychiatry and Neuropsychology 13.3 (2018): 91-97.
[4] Mohamed, Arafath, et al. "The efficacy of psychedelic-assisted therapy in managing post-traumatic stress disorder (PTSD): a new frontier?." Cureus 14.10 (2022).
[5] Denis-Lalonde, Dominique, and Andrew Estefan. "Emerging psychedelic-assisted therapies: Implications for nursing practice." Journal of Mental Health and Addiction Nursing 4.1 (2020): e1-e13.
[6] Cristea, Ioana Alina, Pim Cuijpers, and Joar Øveraas Halvorsen. "The Psychotherapy in MDMA-Assisted Psychotherapy." JAMA psychiatry 81.11 (2024): 1053-1054.
[7] Lal, Rimisha, and Gabrielle Son. "Nursing Staff Training on Compounded Intranasal Ketamine for Treatment-Resistant Depression." (2024).
[8] Penn, Andrew D., et al. "Psychedelic-assisted psychotherapy practices and human caring science: Toward a care-informed model of treatment." Journal of Humanistic Psychology 64.4 (2024): 592-617.